Cost-effectiveness of regional poison control centers

Archives of Internal Medicine

Volumn 156, Issue 22, 1996, Pages 2601-2608

  Harrison, Donald L ^a,b   Draugalis, JoLaine R ^a   Slack, Marion K ^a   Langley, Paul C ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b Clin Invest Regulatory Office   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; HEALTH CARE COST; HEALTH SERVICE; POISON CENTER; PRIORITY JOURNAL;

ACETAMINOPHEN; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DETERGENTS; EMERGENCY SERVICE, HOSPITAL; HUMANS; OVERDOSE; POISON CONTROL CENTERS; UNITED STATES;

EID: 0029837121     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.22.2601     Document Type: Article

References (18)

1. Schauben JL, Spillane J. Poison prevention. US Pharmacist. 1991;16:38-48.
2. Mrvos R, Dean BS, Krenzelok EP. Poison center funding: who should pay? Clin Toxicol. 1994;32:503-508.
3. Litovitz TL, Felberg L, Soloway RA, Ford M, Geller R. 1994 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 1995;13:551-597.
4. Frankenfield DL, Reynolds DR, Regina DA. Pharmacist-initiated poison prevention campaign in a rural community. Am J Hosp Pharm. 1991;8:2657-2658.
5. King WD, Palmisano PA. Poison control centers: can their value be mea-sured? South Med J. 1991;84:722-726.
6. Litovitz TL, Kearney TE, Holm K, Soloway RA, Weisman R, Oderda G. Poison control centers: is there an antidote for budget cuts? Am J Emerg Med. 1994; 12:585-599.
7. Tong TG, Soloway RA. Fiscal antidotes needed. Clin Toxicol. 1994;32:509-511.
8. Harrison DL, Draugalis JR, Slack MK, Tong TG. The production model as a basis for conducting economic evaluations of regional poison control centers. Clin Toxicol. 1995;33:233-237.
9. Centers for Disease Control. A framework for assessing the effectiveness of disease and injury prevention programs. MMWR Morb Mortal Wkly Rep. 1992; 41:RR-3.
10. American Academy of Clinical Toxicology Inc. American Academy of Clinical Toxicology Inc, 1994/1995 Membership Directory. Tampa, Fla: American Academy of Toxicology inc; 1994.
11. Weinstein MC, Fineberg HV, Elstein AS, et al. Clinical Decision Analysis. Philadelphia, Pa: WB Saunders Co; 1980.
12. Barr JT, Schumacher GE. Decision analysis and pharmacoeconomic evaluations. In: Bootman JL, Townsend RJ, McGhan WF, eds. Principles of Pharmacoeconomics. 2nd ed. Cincinnati, Ohio: Harvey Whitney Books Co; 1996: 150-177.
13. TreeAge. DATA for Windows. Boston, Mass: TreeAge Software Inc; 1995.
14. Filandrinos DT, Zunker RJ, Sioris LJ. Costs incurred from unnecessary emergency department visits for treatment of poisonings. Presented at the International Congress of Clinical Toxicology; September 10,1993; New York, NY,
15. Kearney TE, Olson KR, Bero LA, Heard SE, Blanc PD. Health care cost effects of public use of a regional poison control center. West J Med. 1995;162:499-404.
16. Bloom BS, Hillman AL, LaMont B, Liss C, Schwartz JS, Stever GJ. Omeprazole or ranitidine plus metoclopramide for patients with severe erosive oesophagitis: a cost-effectiveness analysis. PharmacoEconomics. 1995;8:343-349.
17. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ. 1994;3: 95-104.
18. Petitti DB. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. New York, NY: Oxford University Press Inc; 1994:187-196.